Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 16, 2023
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
Wed, February 15, 2023
[ Wed, Feb 15th 2023
] - WOPRAI
[ Wed, Feb 15th 2023
] - WOPRAI
Constantine Davides Reiterated (ACST) at Strong Buy and Held Target at $15 on, Feb 15th, 2023
Constantine Davides of EF Hutton, Reiterated "Acasti Pharma Inc." (ACST) at Strong Buy and Held Target at $15 on, Feb 15th, 2023.
Constantine has made no other calls on ACST in the last 4 months.
There is 1 other peer that has a rating on ACST. Out of the 1 peers that are also analyzing ACST, 0 agree with Constantine's Rating of Hold.
This is the rating of the analyst that currently disagrees with Constantine
- Oren Livnat of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $14 on, Thursday, December 15th, 2022
